Waters Buys MOBILion to Expand Proteomics
Waters Corporation has acquired MOBILion Systems to pair its ion mobility separation technology with mass spectrometry for proteomics.
Updated on Nov. 3, 2026 in Biotech
Waters Corporation has acquired MOBILion Systems, developer of Structures for Lossless Ion Manipulations (SLIM) ion mobility separation technology. The deal extends Waters' entry into the proteomics market by combining SLIM separation with its Xevo MRT mass spectrometry.
Why it matters
Proteomics is moving from research laboratories toward routine testing, and the acquisition positions Waters to compete in that transition. The combined platform targets complex biological samples where higher coverage, sensitivity and throughput are needed.
The proteomics LCMS market carries a total addressable market of $2 billion and is growing at a high single-digit rate. The filing does not disclose the purchase price or when combined products will reach customers.
The players
Waters Corporation
Waters Corporation is a global life sciences and diagnostics company known for liquid chromatography and mass spectrometry instruments used in laboratories worldwide.
MOBILion Systems
MOBILion Systems develops Structures for Lossless Ion Manipulations (SLIM) ion mobility separation technology used to enhance mass spectrometry analysis.
The details
The acquisition pairs MOBILion's SLIM ion mobility separation with Waters' Xevo MRT mass spectrometry, and the Xevo TQ Absolute XR tandem quadrupole creates a path from biomarker discovery to targeted verification on one platform. Waters also said the deal could expand blood-based diagnostic test menus over time.
Timeline
Waters announced the acquisition of MOBILion Systems on November 3, 2026.
Roadmap
The deal extends the SLIM ion mobility platform from a standalone separation technology into Waters' commercial mass spectrometry portfolio. It reflects a broader move by life sciences instrument makers to bring proteomics from specialist research labs into routine clinical testing.
Clinical laboratories with existing Waters mass spectrometers may eventually gain access to proteomics-based test menus. Researchers using complex biological samples could see higher coverage and throughput once the combined platform is commercially available.
The takeaway
Advances in proteomics instrumentation can shift analysis from research settings into routine testing, so readers tracking diagnostics should watch how quickly combined platforms reach labs. The timeline for commercial rollout is the key detail to monitor.
Further reading
Explore more Biotech coverage for context on how proteomics tools are reshaping research and diagnostics.
